Sunnybrook Health Sciences Centre
Recipient of 2018 UFCW Canada Award for Leukemia Research
Co-Applicant: Dr. Michael Rauh
Queens University, Kingston, ON
Blood cancer type
Clonal Hemopoiesis is a Risk Factor for Chemotherapy-Related Complications
This study will screen 188 lymphoma patients, over the age of 60, prior to their commencement of chemotherapy. Clonal mutations (called CHIP) are present in 20-30% of lymphoma patients above the age of 70. The hypothesis being tested is that those patients exhibiting a clonal CHIP mutation may have a greater chance to develop chemotherapy-related complications. Testing will also occur at 6 and 12 months post-chemotherapy to investigate possible increased or decreased CHIP mutation levels, and/or any new emerging mutations. This study will have important implications for other types of cancer as well.